<DOC>
	<DOCNO>NCT03014479</DOCNO>
	<brief_summary>The purpose study assess reduction treatment burden 12 week trelagliptin administration patient type 2 diabetes diet exercise therapy .</brief_summary>
	<brief_title>Study QOL Evaluation Trelagliptin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The purpose study assess reduction treatment burden 12 week trelagliptin administration patient type 2 diabetes diet exercise therapy . Eligible subject randomize either study drug ( trelagliptin ) group comparative drug ( daily DPP-4 inhibitor ) group . Treatment burden assess use DTR-QOL questionnaire DTSQ .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>1 . Participants diagnose type 2 diabetes . 2 . Participants stable diet exercise therapy least 12 week prior start screen period . 3 . Participants require DPP4 inhibitor treatment . 4 . Participants HbA1c &gt; =6.5 % &lt; 10.0 % start screen period . 5 . Participants complete DTRQOL questionnaire start screen period . 6 . Participants receive less 2 type medication treatment comorbidities ( hypertension dyslipidemia ) start screen period ( number daily dose ) . 7 . Participants , opinion principal investigator investigator , capable understanding content clinical study comply study protocol requirement . 8 . Participants provide write informed consent prior initiation study procedure . 9 . Participants age &gt; =20 year time inform consent . 10 . Outpatient . 1 . Participants receive oral antidiabetic medication treatment type 2 diabetes start screen period . 2 . Participants diagnose type 1 diabetes . 3 . Participants severe renal impairment renal failure ( e.g. , eGFR &lt; 30 mL/min/1.73 m2 dialysis ) . 4 . Participants serious heart disease cerebrovascular disorder , serious pancreatic , blood , disease . 5 . Participants history gastrointestinal resection . 6 . Participant proliferative diabetic retinopathy . 7 . Participant malignancy . 8 . Participants history hypersensitivity allergy DPP4 inhibitor . 9 . Pregnant , lactate postmenopausal woman . 10 . Participants may need add discontinue concomitant medication change dose study period . 11 . Participants require treatment prohibit concomitant medication study period . 12 . Participants participate clinical study . 13 . Participants assess ineligible study principal investigator investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>